Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

CT Open to Enrollment

A Phase 1b, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG(R)) in Combination Therapy in Subjects with Acute Myeloid Leukemia (AML)

This clinical trial is for men and women diagnosed with acute myeloid leukemia (AML) that has come back after treatment or does not respond to treatment (relapsed and/or refractory [R/R] AML). It is also for men and women with newly diagnosed AML (ndAML) that cannot be treated with standard chemotherapy.

The purpose of this study is to test the safety and preliminary effectiveness of the new experimental combination of CC-486 (also called Onureg® or oral azacitidine) plus venetoclax to find the appropriate dose of CC-486 in this combination.

A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumors Resistant or Refractory to Standard Therapies

This clinical research study is investigating different doses of a study drug called ARX517, to see which dose is safe and has the fewest side effects, and whether or not it is effective in reducing tumor size in participants with prostate cancer or advanced solid tumor(s) with known prostate-specific membrane antigen (PSMA) expression who failed prior standard therapies.
   

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors

This clinical trial is for men and women with advanced solid tumors, such as advanced head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).
   
The purpose of this study is to learn about the safety and effectiveness of combining two investigational anti-cancer drugs, tislelizumab (also known as BGB-A317) and BGB-A425. Investigational means that these drugs have not yet been approved by the U.S. Food and Drug Administration (FDA). 

A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination with Pembrolizumab (KEYtruda) in Subjects with Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (The LENKYN Trial)

This is a research study for adults diagnosed with non-clear cell renal cell carcinoma that has spread outside the kidneys, but they have not yet received any treatment since the disease spread.
   
The purpose of this study is to look at the combination of two drugs, lenvatinib and pembrolizumab, to see how they work together to treat non-clear cell renal cell carcinoma. The study will also look at the side effects participants experience with this combination of drugs.
   

Development of a Novel Web-based Social Reward Task to Test Engagement of the Reward System in Mid- and Late-Life Depression

The purpose of this study is to test a novel assessment of social feedback in adults with depression. It aims to study the association between activity levels, mood, and social aspects of life over the course time.

A Phase I Study to Evaluate the Safety & Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory AML, Intermediate or Higher-Risk Myelodysplastic Syndromes, bcr-abl negative Myeloproliferative Neoplasms, MDS/MPNs, or Multiple Myeloma

This is a clinical trial for adults who were diagnosed with the types of blood cancer acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), bcr-abl negative myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or multiple myeloma (MM), that is ether not responding to standard treatments, the cancer has returned after standard treatment, or there is no standard therapy.

Doxycycline for Emphysema in People Living with HIV

This is a research study to evaluate if the oral medication doxycycline can slow lung damage caused by emphysema in people who also have HIV. This study will also evaluate the safety and tolerability of doxycycline.

Randomized, Double-Blind, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

The purpose of this study is to determine what dose of the oral drug venetoclax in combination with azacitidine (AZA, subcutaneous or intravenous administration) is safe and effective as maintenance therapy in patients with acute myeloid leukemia (AML) in first remission after conventional induction and consolidation chemotherapy.

Single-arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects With Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

The purpose of this study is to learn if the study drug, valemetostat tosylate, can help participants with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) or adult T-cell leukemia/lymphoma (ATL).
   
Valemetostat tosylate is an experimental drug which means that it is being tested and is not yet approved by the United States Food and Drug Administration (FDA). This is the first time that Valemetostat tosylate is being tested in humans.